Stocktoria
Emergent BioSolutions Inc. EBS
Emergent BioSolutions Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $742.9M | $1.0B | $1.0B | $1.1B | $1.8B | $1.6B | $1.1B | $782.4M | $560.9M | $488.8M |
| Gross profit | — | — | $317.6M | $383.0M | $891.3M | $916.3M | — | — | — | — |
| R&D expense | $53.2M | $70.7M | $111.4M | $188.3M | $235.2M | $234.5M | $226.2M | $142.8M | $97.4M | $106.9M |
| SG&A expense | $186.1M | $308.0M | $368.4M | $339.5M | $348.7M | $303.3M | $273.5M | $202.5M | $142.9M | $143.1M |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | $341.4M | $433.8M | $114.1M | $89.8M | $124.3M | $105.5M |
| Interest expense | — | — | $87.9M | $37.3M | $34.5M | $31.3M | $38.4M | $9.9M | $6.6M | $7.6M |
| Income tax | $30.2M | $47.7M | $29.3M | -$7.4M | $83.7M | $102.1M | $22.9M | $18.8M | $36.0M | $36.7M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M | $305.1M | $54.5M | $62.7M | $82.6M | $51.8M |
| EPS (diluted) | $0.93 | $-3.60 | $-14.85 | $-4.22 | $4.06 | $5.67 | $1.04 | $1.22 | $1.71 | $1.13 |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M | $536.0M | $188.0M | $41.8M | $208.1M | $54.6M |
| Free cash flow | $156.8M | $35.8M | -$257.9M | -$149.9M | $96.1M | $395.0M | $101.1M | -$30.3M | $153.3M | -$21.6M |
| Cash & equivalents | $205.4M | $99.5M | $111.7M | $642.6M | $576.1M | $621.3M | $167.8M | $112.2M | $178.3M | $271.5M |
| Inventory | $343.4M | $311.7M | $328.9M | $350.7M | $350.8M | $307.0M | $222.5M | $205.8M | $142.8M | $74.0M |
| Total assets | $1.3B | $1.4B | $1.8B | $3.2B | $3.0B | $2.9B | $2.3B | $2.2B | $1.1B | $970.1M |
| Total liabilities | $796.0M | $906.9M | $1.2B | $1.8B | $1.3B | $1.4B | $1.2B | $1.2B | $157.9M | $373.9M |
| Shareholders' equity | $522.6M | $482.8M | $649.3M | $1.4B | $1.6B | $1.5B | $1.1B | $1.0B | $912.3M | $596.2M |
Growth · year-over-year · Revenue CAGR 4.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -28.8% | -0.5% | -6.1% | -37.0% | +14.0% | +40.6% | +41.4% | +39.5% | +14.8% | -6.5% |
| Net income growth | — | — | — | -196.4% | -28.1% | +459.8% | -13.1% | -24.1% | +59.5% | -17.6% |
| EPS growth | — | — | — | -203.9% | -28.4% | +445.2% | -14.8% | -28.7% | +51.3% | -19.9% |
| Free cash flow growth | +338.0% | — | — | -256.0% | -75.7% | +290.7% | — | -119.8% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.